Association between serum lithium level and incidence of COVID-19 infection.
Br J Psychiatry
; 221(1): 425-427, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1759798
ABSTRACT
An antiviral effect of lithium has been proposed, but never investigated for coronavirus disease 2019 (COVID-19). Using electronic health records of 26 554 patients with documented serum lithium levels during the pandemic, we show that the 6-month COVID-19 infection incidence was lower among matched patients with 'therapeutic' (0.50-1.00) versus 'subtherapeutic' (0.05-0.50) lithium levels (hazard ratio (HR) = 0.82, 95% CI 0.69-0.97, P = 0.017) and among patients with 'therapeutic' lithium levels versus matched patients using valproate (HR = 0.79, 95% CI 0.67-0.92, P = 0.0023). Lower rates of infection were observed for both new COVID-19 diagnoses and positive polymerase chain reaction tests, regardless of underlying psychiatric diagnosis and vaccination status.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Trastorno Bipolar
/
COVID-19
Tipo de estudio:
Estudio observacional
/
Investigación cualitativa
Tópicos:
Vacunas
Límite:
Humanos
Idioma:
Inglés
Revista:
Br J Psychiatry
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
Bjp.2022.42
Similares
MEDLINE
...
LILACS
LIS